Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00094549 · ClinicalTrials.gov registry record · Phase 4
Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
NCT00094549 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 500 participants.
The verdict
NCT00094549, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
Study Summary
The goals of this study are: A. To determine whether olanzapine can help patients with bipolar disorder who currently have mild to moderate mania. B. To assess the safety of olanzapine and any side effects that might be associated with it, as well as the quality of life and functioning of patients treated with olanzapine. C. To assess how olanzapine compares to divalproex.
Interventions
- DRUG placebo
- DRUG olanzapine
- DRUG divalproex sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2004-10 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00094549
The ClinicalTrials.gov registry entry for NCT00094549 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00094549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00094549 about?
NCT00094549 is a clinical study titled "Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder". The goals of this study are: A. To determine whether olanzapine can help patients with bipolar disorder who currently have mild to moderate mania. B. To assess the safety of olanzapine and any side effects that might be associated with it, as well as the quality of life and functioning of patients...
What is the current status of trial NCT00094549?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2004-10. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00094549?
The interventions under investigation include: placebo (DRUG), olanzapine (DRUG), divalproex sodium (DRUG).
Who is sponsoring clinical trial NCT00094549?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.